Treatment of diseases modulated by a h4 receptor agonist
OwnerMichalis Nicolaou, Emile Loria +2inventors
InventorsMichalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin
Life of this patent
Estimating the term…
Abstract
The invention provides a method for the treatment of H4R modulated diseases and/or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.
Claims101
An isolated stereoisomer of tritoqualine having the structure D1 of FIG. 2.
An isolated stereoisomer of tritoqualine having the structure D2 of FIG. 3.
A pharmaceutical composition comprising an isolated stereoisomer D1 of FIG. 2.
A pharmaceutical composition comprising an isolated stereoisomer D2 of FIG. 3.
A method for the treatment of gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.
A method for the treatment of GERD in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.
A method for treating GERD in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor, an anti-H2 drug and an NSAID.
A method for the treatment of food allergy in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.
A pharmaceutical formulation comprising a combination of:
- a. A Histadine decarboxylase inhibitor,
- b. An anti-H1 drug,
- c. an anti-H2 drug, and
- d. a pharmaceutically acceptable carrier.
A method for the treatment of a disease modulated by a H4R agonist comprising administering to a subject an effective amount of a H4R agonist to treat the disease.
A pharmaceutical formulation comprising a combination of
- (a) a H4R agonist,
- (b) one or more of an anti-H1, anti-H2 and anti-H3 drug, and
- (c) a pharmaceutically acceptable carrier.
A method for the treatment of COPD comprising administering to a subject an effective amount of a H4R agonist, an anti-H1 drug and an anticholinergic drug.
Dependencies are inferred from the claim text.